Ruijin Hospital

This early-stage study tests a personalized mRNA vaccine called XP-006 in 20 adults with B-cell Non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The vaccine is custom-made to target each person's unique tumor markers and aims to train the immune …

This study tests whether combining two advanced treatments—glofitamab and CAR-T therapy—can help people with a fast-growing type of lymphoma that has not responded to standard care. About 24 adults with high-risk relapsed or refractory large B-cell lymphoma will receive the combi…

This early-phase study tests a new drug, cizutamig, in 15 adults with moderate to severe ulcerative colitis who have not responded to other treatments. The main goal is to check if the drug is safe and tolerable. Researchers will monitor side effects throughout the study.

This study tests a combination of four drugs (Pola-ZR-Glo) in 30 older adults (70+) with untreated large B-cell lymphoma who cannot tolerate standard chemotherapy. The goal is to control the cancer and improve survival while monitoring side effects and quality of life. Participan…

This study tests a new drug called IBI363 combined with chemotherapy for people with advanced pancreatic cancer that has spread or can't be removed by surgery, and who have already tried one standard treatment. About 48 adults aged 18-75 will receive the combination until their d…

This study tests a new combination of drugs for people aged 65 and older with a fast-growing type of lymphoma called double/triple-hit diffuse large B-cell lymphoma, who cannot have a stem cell transplant. The treatment includes several chemotherapy drugs plus two newer targeted …

This study tests a special PET scan that looks for a protein called Claudin18.2 on pancreatic and stomach cancer cells. The goal is to see if this scan can accurately find the protein, which would help doctors choose the right targeted therapy for each patient. About 64 adults wi…

This study will test two special formulas (amino acid and extensively hydrolyzed) in 360 infants aged 0-6 months who may have cow's milk protein allergy. The goal is to see which formula better relieves symptoms like diarrhea, blood in stool, and skin issues. The study also aims …

This study looks at whether a new ultrasound-based risk score can better predict pressure injuries (bedsores) in critically ill patients than current methods. In the first phase, researchers will check how accurate the score is. In the second phase, some patients will get special…